Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALVAC-HIV vCP1452 and MN rgp120 Phase II Trial
NCT00011037Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of ALVAC-HIV vCP1452 and MN rgp120/HIV-1 in human immunodeficiency virus infection (HIV) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Immunogenicity of vaccine regimens and Safety of vaccine regimens. Status: completed.
02
Drugs
ALVAC-HIV vCP1452MN rgp120/HIV-1
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00011037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00011037.